Holen Sie sich die Stockscreener-App
41.82
0.00%
0.00
Handel nachbörslich:
41.82
Schlusskurs vom Vortag:
$41.82
Offen:
$42.16
24-Stunden-Volumen:
722.45K
Relative Volume:
0.43
Marktkapitalisierung:
$8.64B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-505.61M
KGV:
-15.10
EPS:
-2.7697
Netto-Cashflow:
$-407.32M
1W Leistung:
+4.68%
1M Leistung:
+7.87%
6M Leistung:
+62.41%
1J Leistung:
+175.13%
1-Tages-Spanne:
$40.82
$42.16
1-Wochen-Bereich:
$38.98
$42.92
52-Wochen-Spanne:
$14.47
$42.92
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-410-3120
Adresse
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
41.82 | 8.80B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Bernstein | Mkt Perform |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Eingeleitet | Truist | Hold |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com South Africa
Immunovant stock hits 52-week high at 41.37 USD - Investing.com
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Liquidity Mapping Around (IMVT) Price Events - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. Q1 2027 Earnings Call Summary - finance.yahoo.com
Immunovant Q1 Earnings Call Highlights - MarketBeat
Form 8K Immunovant Inc For: 6 August By Investing.com - Investing.com Nigeria
Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside - TradingView
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress - The Globe and Mail
Immunovant Fiscal Q1 Loss Widens - marketscreener.com
Immunovant, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss - marketscreener.com
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - theglobeandmail.com
Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary - TradingView
Aug 06 (Reuters)Immunovant Q1 Operating Ex - Moomoo
Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026 - TradingView
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - The Manila Times
Immunovant | 8-K: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - Moomoo
IMMUNOVANT Q1 NET INCOME USD -153.224 MILLION VS. IBES ESTIMATE USD -130.2 MILLION - Moomoo
Immunovant earnings up next as analysts eye pipeline pivot - Investing.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming DeadlineIMVT; HSACU; HSAC; and HSACW - TMX Newsfile
IMVT Maintained by JP Morgan -- Price Target Raised to $50.00 - GuruFocus
Immunovant (NASDAQ:IMVT) Price Target Raised to $50.00 - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: Navigating a 21.72% Upside Potential in Biotech Investment - DirectorsTalk Interviews
Perceptive Advisors LLC Lowers Stake in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT.US) will release its earnings report before the market opens on August 6. - moomoo.com
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
ADAR1 Capital Management LLC Grows Stock Position in Immunovant, Inc. $IMVT - MarketBeat
Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT - TradingView
Immunovant, Inc. (IMVT) Stock Analysis: Uncovering A Promising 18.57% Potential Upside - DirectorsTalk Interviews
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy - Seeking Alpha
Immunovant Inc (IMVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - marketscreener.com
Immunovant Inc (IMVT) Cash Flow - TradingKey
Immunovant Insider Sold Shares Worth $263,015, According to a Recent SEC Filing - marketscreener.com
Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunovant Inc (IMVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immunovant Inc (IMVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IMVT|Immunovant Inc|Price:39.410|Chg%:+0.040 - TradingKey
Immunovant CFO Tiago Girao sells $263,014 in company stock By Investing.com - Investing.com India
Immunovant director Atul Pande sells $59,699 in shares By Investing.com - Investing.com Canada
Immunovant director Atul Pande sells $59,699 in shares - Investing.com
Immunovant CFO Tiago Girao sells $263,014 in company stock - Investing.com
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):